Showing results (191-200 of 216) with videos related to
Sort By:
Pageof 22
Biorxiv : the Preprint Server for Biology|July 2, 2020
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19Xuping Xie, Antonio E Muruato, Xianwen Zhang, et al.Biorxiv : the Preprint Server for Biology|March 22, 2022
Parsing the role of NSP1 in SARS-CoV-2 infectionTal Fisher, Avi Gluck, Krishna Narayanan, et al.Cell Reports|June 7, 2022
Parsing the role of NSP1 in SARS-CoV-2 infectionTal Fisher, Avi Gluck, Krishna Narayanan, et al.Mbio|July 28, 2022
A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 VaccineJingen Zhu, Swati Jain, Jian Sha, et al.Biorxiv : the Preprint Server for Biology|January 5, 2021
Potent in vitro anti-SARS-CoV-2 activity by gallinamide A and analogues via inhibition of cathepsin LAnneliese S Ashhurst, Arthur H Tang, Pavla Fajtová, et al.Plos One|July 2, 2015
EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell CarcinomasDongsheng Yue, Hui Li, Juanjuan Che, et al.Frontiers in Immunology|March 27, 2023
A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 BetaBrandon Carter, Pinghan Huang, Ge Liu, et al.Science Translational Medicine|March 13, 2024
An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutationsMichael Westberg, Yichi Su, Xinzhi Zou, et al.Proceedings of the National Academy of Sciences of the United States of America|November 3, 2020
Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infectionWei Li, Chuan Chen, Aleksandra Drelich, et al.Plos Pathogens|September 7, 2021
Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infectionQibin Geng, Wanbo Tai, Victoria K Baxter, et al.Pageof 22